BPGbio

Quick facts

Phase 2 pipeline

• BPM31510 Nanosuspension Injection · Oncology
  BPM31510 is a nanosuspension formulation of buparlisib that inhibits phosphatidylinositol 3-kinase (PI3K) to block tumor cell proliferation and survival signaling.

Phase 1 pipeline

• API 31510
• API 31510 1.5% Topical Cream
• API 31510 3% Topical Cream
• BP31510 in combination with chemotherapy
• BP31510 monotherapy
• BPM31510 Oral Nanosuspension 4%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BPGbio portfolio CI brief
• BPGbio pipeline updates RSS